Indar, Private Join Stock Company

Sphere of business:
- production and purification of insulin substance;
- production of insulin preparations;
- production of infusion solutions;
- production of organ preparations;
- selling, market exploration and information-medical services;
- research activity (development of new drugs, technologies etc.).

Information about production division

Enterprise was built under licence of firm “Hoechst” (Germany). Designing, construction and assembling of insulin division was carried out by Consortium Glatt/Linde (Germany) according to DIN EN ISO 9001 standard.
There is an autonomous energy and heat supply.
Water preparation is realized in the setting of firm “Letzner”. Purification of water includes the following steps: deironing, inverse osmose, ozonization, ultra-violet irradiation, filtration, distillation.
Instruments and equipment used during construction of production divisions meet the requirements of “clean rooms”. Three-stage air purification and autonomous control of climate conditions maintain stable functioning conditions of “clean rooms”. Total area of “clean rooms” is 700 square meters.
Insulin production division consists of three departments: substance production and purification department, finished insulin products production, infusion solutions production.
Five laboratories (physical-chemical, chemical-analytical, microbiological, ecological, biological) control raw materials, subsidiary substances, finished products and production process at 700 indices according to Pharmacopoeia standards (Eur. Ph., BP, USP, DAB 10). Laboratories are accredited by Ukrainian State Center of standardization, metrology and certification.

CJSC “Indar” has registered and produces:
- porcine insulins - Monodarum, Monodarum B, MC Suinsulinum- Long,
MC Suinsulinum-Ultralong;
- human insulins - Humodarum R, Humodarum C25, Humodarum B;
- infusion solutions – Sodium Chloride 0,9%, Glucose 5%, Neohemodes, Reopolyglycine, blood preservative- Gluegyzyr.

Clinical tests have been concluded and registration of porcine insulins – Monodarum C15, Monodarum C30, Monodarum C50 - and human insulins – Humodarum C15, Humodarum C50 - is completed. By the end of the year these drugs appear in the market.

Productive capacity of enterprise is 12 million of insulin vials per year (10 ml vials, 40 IU/ml) and 1,5 million of infusion solutions (200ml and 400ml vials).
Quality of medical products meets the world requirements. Porcine monocomponent neutral insulins.